

Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 8-K

Valeant Pharmaceuticals International, Inc.
Form 8-K
January 09, 2018

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): January 9, 2018

Valeant Pharmaceuticals International, Inc.
(Exact Name of Registrant as Specified in Its Charter)

| | | |
|---|---|--|
| British Columbia, Canada (State or Other Jurisdiction of Incorporation or Organization) | 001-14956 (Commission File Number) | 98-0448205 (I.R.S. Employer Identification Number) |
| (Address of Principal Executive Offices)(Zip Code) | 2150 St. Elzéar Blvd. West Laval, Quebec Canada H7L 4A8 | |
| (Registrant's telephone number, including area code) | 514-744-6792 | |
| (Former name or former address, if changed since last report) | | |

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

Joseph C. Papa, Chairman and Chief Executive Officer of Valeant Pharmaceuticals International, Inc., will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 10, 2018, at 10:30 a.m. PST (1:30 p.m. EST). The slides that will be used for the presentation are furnished as Exhibit 99.1 to this Form 8-K.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Valeant Pharmaceuticals International, Inc. Presentation Slides

3

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VALEANT PHARMACEUTICALS INTERNATIONAL,
INC.

By: /s/ Christina Ackermann

Name: Christina Ackermann

Title: Executive Vice President and General Counsel

Date: January 9, 2018

4

EXHIBIT INDEX

Exhibit Number Description

99.1 Valeant Pharmaceuticals International, Inc. Presentation Slides

5